SIHUAN PHARM0460.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, SIHUAN PHARM (0460.HK) trades at a P/E of 18.90x, P/B of 0.93x, P/S of 2.19x, and a dividend yield of 1.54%.
Longitudinal percentile comparison: P/E sits at the 63rd percentile over the trailing 10Y window (vs. 2nd percentile over 3Y); P/B sits at the 14th percentile over the trailing 10Y window (vs. 1st percentile over 3Y); P/S sits at the 3rd percentile over the trailing 10Y window (vs. 1st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 68th percentile within its industry and the 71st percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 2.47%, ranking at the 47th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 48.4 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Of the 2.47% total shareholder yield, 1.54% is paid out as dividends and roughly 0.93% is implied to come from buybacks — both channels are meaningfully in play. SIHUAN PHARM operates in the Pharmaceutical Chemistry sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 0460 · SEHK: 0460 · 0460
Want the full picture on whether SIHUAN PHARM (0460.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 18.90 | ||||||
| P/B (MRQ) | 0.93 | ||||||
| P/S (TTM) | 2.19 | ||||||
| Dividend Yield | 1.54% | ||||||
| Buyback + Div Yield | 2.47% |